BioSpace News Archive

IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced the appointment of Hilda Scharen-Guivel to the Iradimed Board of Directors, effective October 4, 2022.

STRATA Skin Sciences, Inc. announced the company will present at the Midcap Rodeo: Windy City Roundup 2022 and the LD Micro Main Event XV.

Mersana Therapeutics, Inc. (NASDAQ: MRSN) today announced the completion of patient enrollment in UPLIFT, the company’s single-arm registrational trial of UpRi in platinum-resistant ovarian cancer.

Rhythm Pharmaceuticals, Inc. announced the appointment of Dana Washburn, M.D., as Senior Vice President of Clinical Development and as a member of the Company’s Executive Leadership Team, effective September 26, 2022.

Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 1 clinical trial for LYL845.

Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the third quarter 2022 following the close of market on Thursday, November 3, 2022.

Haemonetics Corporation announced that the Company intends to publish second quarter fiscal year 2023 financial results at 6:00 am ET on Monday, November 7, 2022.

Accuray Incorporated announced that the company will host a key opinion leader discussion with analysts and investors on Monday, October 24, 2022, in conjunction with the American Society of Radiation Oncology Annual Meeting.

Teva Pharmaceutical Industries Ltd. announced that it will issue a press release on its third quarter 2022 financial results on Thursday, November 3, 2022 at 7:00 a.m. ET.

Kezar Life Sciences, Inc. announced that the Compensation Committee of the company’s Board of Directors granted three employees nonqualified stock options to purchase 85,000 shares of its common stock with an exercise price of $8.80 per share, which is equal to the closing price of Kezar’s common stock on October 3, 2022, the grant date of the awards.